In the specialized field of biochemical research and molecular engineering, the K237 peptide has emerged as a subject of significant interest. As an enthusiast who follows advancements in biotechnology, I have spent considerabl A peptide fusion protein inhibits angiogenesis and tumor e time reviewing the literature surrounding this unique 12-mer sequence. Known by its specific amino acid sequence, HTMYYHHYQHHL, this peptide represents a sophisticated tool in the design of targeted molecular delivery systems.
Understanding the Structure and Function of K237
The K237 peptide is a synthetic ligand characterized by its high affinity for the VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, Biotinylated variants, and similar structures. My analysis of various studies indicates that this sequence was originally isolated through phage display library screening. The primary mechanism of action is its ability to functionally disrupt the interaction between VEGF and the KDR receptor. By occupying this specific binding site, the peptide acts as a competitive antagonist.
From a technical standp VEGF receptor KDR/Flk-1 (K237), Peptide Aptamer, oint, the K237 peptide is typically produced via solid-phase peptide synthesis (SPPS), a process that ensures high purity and consistency for laboratory applications. This level of precision is critical when the goal is to bind to the KDR receptors with the specificity required for experimental molecular probes.
Innovations in Targeted Delivery
One of the most exciting applications I have observed involves the development of nanoparticles conjugated with K237-(HTMYYHHYQHHL) peptides. These delivery systems are engineered to navigate complex biological environments. For instance, res 108010010994 K237 peptide Proteins 0.000 description 1; 208000008839 Kidney Neoplasms Diseases 0.000 description 1; 206010058467 Lung neoplasm malignant earchers have utilized DSPE-PEG1000-K237 and by Q Qian · 2019 · Cited by 66 — This K237 peptide (HTMYYHHYQHHL-NH2) binds to the KDR/Flk-1 tyrosine kinase, one of two key receptors for vascular endothelial growth factor which are DSPE-PEG2000-K237 to anchor the targeting ligand to the surface of lipid-based carriers.
These constructs are designed for high stability, and in many cases, they could accurately target tumor neovasculature. By leveraging the anti-angiogenesis effect from VEGFR2-blocking by K237 peptide, these carriers aim to concentrate their payload precisely where the receptors are most densely expressed. My review of recent papers—such as those focusing on paclitaxel-loaded nanoparticles conjugated with K237 peptide—highlights how this approach can increase the targeting efficiency of TSL (thermosensitive liposomes) and other controlled-release vehicles.
Technical Synthesis and Characterization
The complexity of these systems is evident in projects like the synthesis of K237-CS (PTX)-g-PNIPAM NPs. The integration of peptides into larger polymer networks requires careful handling of chemical reagents and reaction conditions. For those interested in the structural characterization of these materials, Multi-targeting Peptide-Functionalized Nanoparticles data often includes:
* TEM and DLS analysis: Confirming that the resulting particles are uniform in size and lack significant agglomeration.
* Radiolabeling: The use of probes like 131I-K237 to track biodistribution and receptor binding kinetics in controlled environments.
Research Observations
The scientific community continues to explore how the K237 peptide binds to the vascular endothelial growth factor receptor with such high fidelity. Whether it is classified under technical categories like 108010010994 K237 peptide Proteins or used in the development of novel molecular probes, the consensus is clear: the precision DSPE-PEG2000-K237 is a PEG compound which composed of DSPE and a KDR targeting peptide (K237). K237 can functionally disrupt the interaction between VEGF of this 12-mer sequence is a cornerstone of modern ligand-directed research.
While my interest remains strictly academic and focused on the technological potential of synthetic peptides, the advancements in conjugation chemistry—moving from simple biotinylated forms to complex, responsive nanotechnology—showcase the incredible trajectory of this research area. Observing how K237 functions as a molecular navigator continues to provide valuable insights into the future of b Neovasculature and circulating tumor cells dual-targeting iomimetic design and targeted delivery strategies.